AI combined with tools such as the PSMA PET (Prostate Specific Membrane Antigen Positron Emission Tomography) for focal localization of prostate cancer and metastases, TRUS (transrectal ultrasound scan) fusion biopsies with MRI for superior prostate mapping and radiotherapy, and radiogenomics to identify new genetic biomarkers are only a few hot areas for exploration [63,64]. This evidence concerns the gene FOLH1 and prostate carcinoma.